MetaCap

Dogwood Therapeutics (DWTX) vs Grace Therapeutics (GRCE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Grace Therapeutics (GRCE) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 46.4% versus a loss of 83.7%. Over five years, GRCE leads with a -79.3% price change compared with -99.2% for DWTX. Dogwood Therapeutics is the larger company by market cap ($39.6 million vs $36.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DWTX-83.68%GRCE-46.39%
+68%-11%-91%
Nov 21, 20251 yearNov 20, 2026
DWTX-99.25%GRCE-80.48%
+67%-20%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DWTX versus GRCE key metrics
MetricDWTXGRCE
Share price$1.04$1.71
Market cap$39.57M$35.97M
1-day change-2.36%-0.58%
YTD return-75.12%-50.58%
1-year return-83.68%-46.39%
5-year return-99.16%-79.35%
P/E ratio (TTM)0.10—
EPS (TTM)$10.26$-1.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-34.26M$-7.79M
52-week high$7.04$5.18
52-week low$0.901$1.64
Distance from 52-week high-85.31%-66.99%
Analyst consensusnonenone
Avg. price target upside+1252.66%+243.27%
Average volume89.88K119.27K
Shares outstanding38.23M21.04M
Employees85
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GRCE has outperformed DWTX by 37.3 percentage points over the past year.

About Dogwood Therapeutics

DWTX stock →

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Grace Therapeutics

GRCE stock →

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

DWTX vs GRCE FAQ

Which is bigger, Dogwood Therapeutics or Grace Therapeutics?

Dogwood Therapeutics (DWTX) is larger, with a market capitalization of $39.57M compared with $35.97M for Grace Therapeutics (GRCE).

Which stock has performed better over the past year, DWTX or GRCE?

GRCE returned -46.39% over the past 12 months, compared with -83.68% for DWTX (price return, excluding dividends). Past performance does not predict future results.

Are Dogwood Therapeutics and Grace Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons